James Huang has bought stock on 12 days since Dec 2019

James Zuie-chin Huang, M.B.A., is a seasoned biotechnology executive with over 30 years of experience as an entrepreneur, investor, and key opinion leader in the healthcare sector.( He is the Founder and Managing Partner of Panacea Venture, a significant shareholder of Connect Biopharma Holdings Limited (Nasdaq: CNTB), and serves as a Director on its Board, appointed effective February 12, 2024.( In this role, Huang contributes his deep industry insights to advance the company's pipeline, including rademikibart for atopic dermatitis and asthma.(

Huang's career highlights include prior roles as Managing Partner at Kleiner Perkins China (focusing on life sciences) and Vivo Ventures (leading China investments), President of Anesiva (a pain-management biopharma), and senior positions in business development, sales, marketing, and R&D at Tularik Inc. (acquired by Amgen), GlaxoSmithKline, Bristol-Myers Squibb, and ALZA Corp. (acquired by Johnson & Johnson).( He currently serves on the boards of companies such as Kindstar Global, TacTiva Therapeutics, TriArm Therapeutics, Chime Biologics, and others.( Huang holds an M.B.A. from the Stanford Graduate School of Business and a B.S. in chemical engineering from the University of California, Berkeley.( Recently, as a director, he purchased 1.16 million shares of CNTB on March 31 for $4 million, signaling confidence in the company.(

Written by Perplexity from public sources.